Tenax Therapeutics, Inc. (NASDAQ: TENX) Stock Competitors & Peer Comparison
See TENX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TENX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TENX | $13.44 | +0.98% | 356.5M | -9.60 | -$1.40 | N/A |
| VRTX | $496.07 | +2.49% | 125.9B | 26.07 | $19.03 | N/A |
| REGN | $784.36 | +1.59% | 80.8B | 17.19 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $865.04 | -1.17% | 53.8B | 78.07 | $11.08 | N/A |
| RVMDW | $11.50 | +8.59% | 45.1B | -1.60 | -$7.21 | N/A |
| RVMD | $205.15 | +3.71% | 43.6B | -23.26 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $348.27 | +5.60% | 37.2B | 61.32 | $5.68 | N/A |
| ALNY | $219.20 | +1.43% | 29.3B | 39.50 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
TENX vs VRTX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, VRTX has a market cap of 125.9B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while VRTX trades at $496.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas VRTX's P/E ratio is 26.07. In terms of profitability, TENX's ROE is -0.62%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, TENX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
TENX vs REGN Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, REGN has a market cap of 80.8B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while REGN trades at $784.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas REGN's P/E ratio is 17.19. In terms of profitability, TENX's ROE is -0.62%, compared to REGN's ROE of +0.14%. Regarding short-term risk, TENX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for TENX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
TENX vs VRNA Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TENX's ROE is -0.62%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, TENX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for TENX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
TENX vs ARGX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ARGX has a market cap of 53.8B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ARGX trades at $865.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ARGX's P/E ratio is 78.07. In terms of profitability, TENX's ROE is -0.62%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, TENX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
TENX vs RVMDW Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, RVMDW has a market cap of 45.1B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while RVMDW trades at $11.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas RVMDW's P/E ratio is -1.60. In terms of profitability, TENX's ROE is -0.62%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, TENX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for TENX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
TENX vs RVMD Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, RVMD has a market cap of 43.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while RVMD trades at $205.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas RVMD's P/E ratio is -23.26. In terms of profitability, TENX's ROE is -0.62%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, TENX is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for TENX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
TENX vs SGEN Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TENX's ROE is -0.62%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TENX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for TENX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
TENX vs ONC Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ONC has a market cap of 37.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ONC trades at $348.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ONC's P/E ratio is 61.32. In terms of profitability, TENX's ROE is -0.62%, compared to ONC's ROE of +0.14%. Regarding short-term risk, TENX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
TENX vs ALNY Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ALNY has a market cap of 29.3B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ALNY trades at $219.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ALNY's P/E ratio is 39.50. In terms of profitability, TENX's ROE is -0.62%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, TENX is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ALNY's competition here
Insmed Incorporated (NASDAQ: INSM)
TENX vs INSM Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, INSM has a market cap of 28.4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while INSM trades at $131.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas INSM's P/E ratio is -28.69. In terms of profitability, TENX's ROE is -0.62%, compared to INSM's ROE of -1.11%. Regarding short-term risk, TENX is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for TENX.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
TENX vs ROIV Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ROIV has a market cap of 26.3B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ROIV trades at $36.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ROIV's P/E ratio is -34.57. In terms of profitability, TENX's ROE is -0.62%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, TENX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
TENX vs INCY Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while INCY trades at $120.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas INCY's P/E ratio is 16.20. In terms of profitability, TENX's ROE is -0.62%, compared to INCY's ROE of +0.30%. Regarding short-term risk, TENX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for TENX.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
TENX vs BNTX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, BNTX has a market cap of 23.5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while BNTX trades at $93.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas BNTX's P/E ratio is -16.95. In terms of profitability, TENX's ROE is -0.62%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, TENX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check BNTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
TENX vs MRNA Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, MRNA has a market cap of 23.5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while MRNA trades at $59.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas MRNA's P/E ratio is -7.26. In terms of profitability, TENX's ROE is -0.62%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, TENX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for TENX.Check MRNA's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
TENX vs UTHR Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, UTHR has a market cap of 22.9B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while UTHR trades at $538.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas UTHR's P/E ratio is 19.28. In terms of profitability, TENX's ROE is -0.62%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, TENX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for TENX.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
TENX vs BGNE Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TENX's ROE is -0.62%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, TENX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for TENX.Check BGNE's competition here
Genmab A/S (NASDAQ: GMAB)
TENX vs GMAB Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, GMAB has a market cap of 19.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while GMAB trades at $31.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas GMAB's P/E ratio is 23.55. In terms of profitability, TENX's ROE is -0.62%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, TENX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for TENX.Check GMAB's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
TENX vs DNA-WT Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TENX's ROE is -0.62%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, TENX is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for TENX.Check DNA-WT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
TENX vs BBIO Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while BBIO trades at $84.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas BBIO's P/E ratio is -22.59. In terms of profitability, TENX's ROE is -0.62%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, TENX is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for TENX.Check BBIO's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
TENX vs NBIX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, NBIX has a market cap of 16.4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while NBIX trades at $163.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas NBIX's P/E ratio is 23.61. In terms of profitability, TENX's ROE is -0.62%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, TENX is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
TENX vs JAZZ Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, JAZZ has a market cap of 16.1B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while JAZZ trades at $256.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas JAZZ's P/E ratio is 9.57. In terms of profitability, TENX's ROE is -0.62%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, TENX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for TENX.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
TENX vs ASND Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ASND has a market cap of 15.9B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ASND trades at $255.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ASND's P/E ratio is -105.54. In terms of profitability, TENX's ROE is -0.62%, compared to ASND's ROE of -56.42%. Regarding short-term risk, TENX is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
TENX vs EXEL Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, EXEL has a market cap of 13.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while EXEL trades at $54.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas EXEL's P/E ratio is 15.45. In terms of profitability, TENX's ROE is -0.62%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, TENX is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for TENX.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
TENX vs KRTX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TENX's ROE is -0.62%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TENX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
TENX vs ARWR Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ARWR has a market cap of 12.3B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ARWR trades at $87.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ARWR's P/E ratio is -38.96. In terms of profitability, TENX's ROE is -0.62%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, TENX is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
TENX vs BMRN Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, BMRN has a market cap of 12.3B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while BMRN trades at $63.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas BMRN's P/E ratio is 30.68. In terms of profitability, TENX's ROE is -0.62%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, TENX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for TENX.Check BMRN's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
TENX vs HALO Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, HALO has a market cap of 12.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while HALO trades at $103.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas HALO's P/E ratio is 19.24. In terms of profitability, TENX's ROE is -0.62%, compared to HALO's ROE of +1.81%. Regarding short-term risk, TENX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for TENX.Check HALO's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
TENX vs MDGL Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while MDGL trades at $510.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas MDGL's P/E ratio is -39.85. In terms of profitability, TENX's ROE is -0.62%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, TENX is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for TENX.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
TENX vs TECH Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while TECH trades at $72.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas TECH's P/E ratio is 37.26. In terms of profitability, TENX's ROE is -0.62%, compared to TECH's ROE of +0.05%. Regarding short-term risk, TENX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for TENX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
TENX vs RNAM Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TENX's ROE is -0.62%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, TENX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for TENX.Check RNAM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
TENX vs SMMT Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, SMMT has a market cap of 11.1B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while SMMT trades at $13.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas SMMT's P/E ratio is -8.72. In terms of profitability, TENX's ROE is -0.62%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, TENX is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for TENX.Check SMMT's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
TENX vs AXSM Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, AXSM has a market cap of 10.9B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while AXSM trades at $212.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas AXSM's P/E ratio is -55.55. In terms of profitability, TENX's ROE is -0.62%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, TENX is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for TENX.Check AXSM's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
TENX vs PRAX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, PRAX has a market cap of 10.1B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while PRAX trades at $360.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas PRAX's P/E ratio is -27.90. In terms of profitability, TENX's ROE is -0.62%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, TENX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for TENX.Check PRAX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
TENX vs KRYS Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while KRYS trades at $326.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas KRYS's P/E ratio is 40.91. In terms of profitability, TENX's ROE is -0.62%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, TENX is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for TENX.Check KRYS's competition here
Abivax S.A. (NASDAQ: ABVX)
TENX vs ABVX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ABVX has a market cap of 9.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ABVX trades at $130.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ABVX's P/E ratio is -68.63. In terms of profitability, TENX's ROE is -0.62%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, TENX is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ABVX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
TENX vs RXDX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TENX's ROE is -0.62%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TENX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check RXDX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
TENX vs CYTK Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while CYTK trades at $76.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas CYTK's P/E ratio is -13.17. In terms of profitability, TENX's ROE is -0.62%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, TENX is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for TENX.Check CYTK's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
TENX vs IONS Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, IONS has a market cap of 9.4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while IONS trades at $56.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas IONS's P/E ratio is -32.88. In terms of profitability, TENX's ROE is -0.62%, compared to IONS's ROE of -1.11%. Regarding short-term risk, TENX is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for TENX.Check IONS's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
TENX vs PTGX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, PTGX has a market cap of 9.4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while PTGX trades at $145.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas PTGX's P/E ratio is 141.62. In terms of profitability, TENX's ROE is -0.62%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, TENX is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
TENX vs NUVL Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas NUVL's P/E ratio is -21.79. In terms of profitability, TENX's ROE is -0.62%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TENX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for TENX.Check NUVL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
TENX vs SYRE Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, SYRE has a market cap of 9.1B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while SYRE trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas SYRE's P/E ratio is -53.80. In terms of profitability, TENX's ROE is -0.62%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, TENX is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for TENX.Check SYRE's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
TENX vs CRNX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while CRNX trades at $84.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas CRNX's P/E ratio is -16.68. In terms of profitability, TENX's ROE is -0.62%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TENX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check CRNX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
TENX vs KYMR Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, KYMR has a market cap of 8.8B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while KYMR trades at $107.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas KYMR's P/E ratio is -33.60. In terms of profitability, TENX's ROE is -0.62%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, TENX is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for TENX.Check KYMR's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
TENX vs IMGN Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TENX's ROE is -0.62%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TENX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for TENX.Check IMGN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
TENX vs PCVX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while PCVX trades at $58.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas PCVX's P/E ratio is -7.61. In terms of profitability, TENX's ROE is -0.62%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, TENX is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
TENX vs BPMC Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TENX's ROE is -0.62%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, TENX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for TENX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
TENX vs APGE Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while APGE trades at $134.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas APGE's P/E ratio is -31.14. In terms of profitability, TENX's ROE is -0.62%, compared to APGE's ROE of -0.33%. Regarding short-term risk, TENX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for TENX.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
TENX vs ALKS Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ALKS has a market cap of 8.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ALKS trades at $49.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ALKS's P/E ratio is 51.76. In terms of profitability, TENX's ROE is -0.62%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, TENX is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ALKS's competition here
Immunovant, Inc. (NASDAQ: IMVT)
TENX vs IMVT Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while IMVT trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas IMVT's P/E ratio is -14.17. In terms of profitability, TENX's ROE is -0.62%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, TENX is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for TENX.Check IMVT's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
TENX vs CERE Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas CERE's P/E ratio is -16.47. In terms of profitability, TENX's ROE is -0.62%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TENX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for TENX.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
TENX vs IBRX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, IBRX has a market cap of 8B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while IBRX trades at $7.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas IBRX's P/E ratio is -7.88. In terms of profitability, TENX's ROE is -0.62%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, TENX is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
TENX vs RYTM Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while RYTM trades at $115.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas RYTM's P/E ratio is -37.18. In terms of profitability, TENX's ROE is -0.62%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, TENX is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for TENX.Check RYTM's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
TENX vs TGTX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, TGTX has a market cap of 7.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while TGTX trades at $49.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas TGTX's P/E ratio is 18.03. In terms of profitability, TENX's ROE is -0.62%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, TENX is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check TGTX's competition here
Metsera, Inc. (NASDAQ: MTSR)
TENX vs MTSR Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TENX's ROE is -0.62%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, TENX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for TENX.Check MTSR's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
TENX vs COGT Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, COGT has a market cap of 7.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while COGT trades at $42.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas COGT's P/E ratio is -20.09. In terms of profitability, TENX's ROE is -0.62%, compared to COGT's ROE of -0.83%. Regarding short-term risk, TENX is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for TENX.Check COGT's competition here
Merus N.V. (NASDAQ: MRUS)
TENX vs MRUS Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TENX's ROE is -0.62%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, TENX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for TENX.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
TENX vs ACLX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TENX's ROE is -0.62%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, TENX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ACLX's competition here
CG Oncology Inc. (NASDAQ: CGON)
TENX vs CGON Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while CGON trades at $75.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas CGON's P/E ratio is -27.92. In terms of profitability, TENX's ROE is -0.62%, compared to CGON's ROE of -0.25%. Regarding short-term risk, TENX is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for TENX.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
TENX vs RETA Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas RETA's P/E ratio is -66.29. In terms of profitability, TENX's ROE is -0.62%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TENX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for TENX.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
TENX vs BLTE Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while BLTE trades at $163.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas BLTE's P/E ratio is -87.19. In terms of profitability, TENX's ROE is -0.62%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, TENX is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for TENX.Check BLTE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
TENX vs CAI Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, CAI has a market cap of 6.4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while CAI trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas CAI's P/E ratio is 63.89. In terms of profitability, TENX's ROE is -0.62%, compared to CAI's ROE of +0.19%. Regarding short-term risk, TENX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for TENX.Check CAI's competition here
Erasca, Inc. (NASDAQ: ERAS)
TENX vs ERAS Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ERAS has a market cap of 6.4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ERAS trades at $18.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ERAS's P/E ratio is -19.80. In terms of profitability, TENX's ROE is -0.62%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, TENX is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ERAS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
TENX vs SRRK Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, SRRK has a market cap of 6.3B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while SRRK trades at $52.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas SRRK's P/E ratio is -15.34. In terms of profitability, TENX's ROE is -0.62%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, TENX is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for TENX.Check SRRK's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
TENX vs CNTA Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas CNTA's P/E ratio is -22.63. In terms of profitability, TENX's ROE is -0.62%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TENX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for TENX.Check CNTA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
TENX vs MIRM Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while MIRM trades at $100.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas MIRM's P/E ratio is -6.92. In terms of profitability, TENX's ROE is -0.62%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, TENX is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for TENX.Check MIRM's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
TENX vs XENE Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while XENE trades at $63.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas XENE's P/E ratio is -13.48. In terms of profitability, TENX's ROE is -0.62%, compared to XENE's ROE of -0.44%. Regarding short-term risk, TENX is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for TENX.Check XENE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
TENX vs PTCT Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while PTCT trades at $73.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas PTCT's P/E ratio is -31.46. In terms of profitability, TENX's ROE is -0.62%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, TENX is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for TENX.Check PTCT's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
TENX vs ORKA Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ORKA has a market cap of 6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ORKA trades at $98.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ORKA's P/E ratio is -50.94. In terms of profitability, TENX's ROE is -0.62%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, TENX is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ORKA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
TENX vs LGND Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while LGND trades at $293.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas LGND's P/E ratio is 32.18. In terms of profitability, TENX's ROE is -0.62%, compared to LGND's ROE of +0.20%. Regarding short-term risk, TENX is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for TENX.Check LGND's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
TENX vs TVTX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, TVTX has a market cap of 5.7B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while TVTX trades at $61.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas TVTX's P/E ratio is -136.27. In terms of profitability, TENX's ROE is -0.62%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, TENX is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check TVTX's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
TENX vs CDTX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TENX's ROE is -0.62%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, TENX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
TENX vs ABCM Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TENX's ROE is -0.62%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TENX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
TENX vs ISEE Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TENX's ROE is -0.62%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TENX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
TENX vs APLS Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas APLS's P/E ratio is 38.35. In terms of profitability, TENX's ROE is -0.62%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TENX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for TENX.Check APLS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
TENX vs CRSP Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while CRSP trades at $53.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas CRSP's P/E ratio is -11.24. In terms of profitability, TENX's ROE is -0.62%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, TENX is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for TENX.Check CRSP's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
TENX vs DFTX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while DFTX trades at $46.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas DFTX's P/E ratio is N/A. In terms of profitability, TENX's ROE is -0.62%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, TENX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for TENX.Check DFTX's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
TENX vs ACAD Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ACAD has a market cap of 5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ACAD trades at $29.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ACAD's P/E ratio is 14.18. In terms of profitability, TENX's ROE is -0.62%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, TENX is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
TENX vs DYN Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while DYN trades at $26.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas DYN's P/E ratio is -8.15. In terms of profitability, TENX's ROE is -0.62%, compared to DYN's ROE of -0.64%. Regarding short-term risk, TENX is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for TENX.Check DYN's competition here
Veradermics, Incorporated (NYSE: MANE)
TENX vs MANE Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, MANE has a market cap of 4.8B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while MANE trades at $114.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas MANE's P/E ratio is -36.42. In terms of profitability, TENX's ROE is -0.62%, compared to MANE's ROE of -0.84%. Regarding short-term risk, TENX is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for TENX.Check MANE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
TENX vs TERN Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas TERN's P/E ratio is -51.41. In terms of profitability, TENX's ROE is -0.62%, compared to TERN's ROE of -0.20%. Regarding short-term risk, TENX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for TENX.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
TENX vs EWTX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, EWTX has a market cap of 4.7B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while EWTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas EWTX's P/E ratio is -23.52. In terms of profitability, TENX's ROE is -0.62%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, TENX is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check EWTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
TENX vs FOLD Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TENX's ROE is -0.62%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, TENX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for TENX.Check FOLD's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
TENX vs DNTH Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while DNTH trades at $108.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas DNTH's P/E ratio is -26.25. In terms of profitability, TENX's ROE is -0.62%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, TENX is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for TENX.Check DNTH's competition here
Celcuity Inc. (NASDAQ: CELC)
TENX vs CELC Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while CELC trades at $92.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas CELC's P/E ratio is -23.79. In terms of profitability, TENX's ROE is -0.62%, compared to CELC's ROE of -2.45%. Regarding short-term risk, TENX is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for TENX.Check CELC's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
TENX vs AKRO Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TENX's ROE is -0.62%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, TENX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for TENX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
TENX vs ALPN Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TENX's ROE is -0.62%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TENX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
TENX vs ELVN Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ELVN has a market cap of 4.3B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ELVN trades at $60.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ELVN's P/E ratio is -36.20. In terms of profitability, TENX's ROE is -0.62%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, TENX is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ELVN's competition here
Opthea Limited (NASDAQ: OPT)
TENX vs OPT Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas OPT's P/E ratio is -1.52. In terms of profitability, TENX's ROE is -0.62%, compared to OPT's ROE of +1.18%. Regarding short-term risk, TENX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for TENX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
TENX vs PRTC Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas PRTC's P/E ratio is -3.78. In terms of profitability, TENX's ROE is -0.62%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, TENX is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for TENX.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
TENX vs MRTX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TENX's ROE is -0.62%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TENX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check MRTX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
TENX vs VKTX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while VKTX trades at $34.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas VKTX's P/E ratio is -8.28. In terms of profitability, TENX's ROE is -0.62%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, TENX is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check VKTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
TENX vs ADPT Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, ADPT has a market cap of 4B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while ADPT trades at $24.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas ADPT's P/E ratio is -46.17. In terms of profitability, TENX's ROE is -0.62%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, TENX is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for TENX.Check ADPT's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
TENX vs DNLI Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, DNLI has a market cap of 3.9B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while DNLI trades at $24.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas DNLI's P/E ratio is -8.62. In terms of profitability, TENX's ROE is -0.62%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, TENX is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for TENX.Check DNLI's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
TENX vs TLX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, TLX has a market cap of 3.9B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while TLX trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas TLX's P/E ratio is -626.09. In terms of profitability, TENX's ROE is -0.62%, compared to TLX's ROE of -0.02%. Regarding short-term risk, TENX is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check TLX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
TENX vs CPRX Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas CPRX's P/E ratio is 12.30. In terms of profitability, TENX's ROE is -0.62%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TENX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for TENX.Check CPRX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
TENX vs LEGN Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while LEGN trades at $20.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas LEGN's P/E ratio is -30.51. In terms of profitability, TENX's ROE is -0.62%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, TENX is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for TENX.Check LEGN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
TENX vs RYZB Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas RYZB's P/E ratio is -57.86. In terms of profitability, TENX's ROE is -0.62%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, TENX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for TENX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
TENX vs CBAY Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas CBAY's P/E ratio is -32.81. In terms of profitability, TENX's ROE is -0.62%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, TENX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for TENX.Check CBAY's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
TENX vs NAMSW Comparison August 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TENX stands at 356.5M. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, TENX is priced at $13.44 on the NASDAQ, while NAMSW trades at $17.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TENX currently has a P/E ratio of -9.60, whereas NAMSW's P/E ratio is -9.40. In terms of profitability, TENX's ROE is -0.62%, compared to NAMSW's ROE of -0.38%. Regarding short-term risk, TENX is more volatile compared to NAMSW. This indicates higher risk in terms of short-term price fluctuations for TENX.Check NAMSW's competition here